Literature DB >> 27426745

Translation Initiation Factors: Reprogramming Protein Synthesis in Cancer.

Jennifer Chu1, Marie Cargnello2, Ivan Topisirovic3, Jerry Pelletier4.   

Abstract

Control of mRNA translation plays a crucial role in the regulation of gene expression and is critical for cellular homeostasis. Dysregulation of translation initiation factors has been documented in several pathologies including cancer. Aberrant function of translation initiation factors leads to translation reprogramming that promotes proliferation, survival, angiogenesis, and metastasis. In such context, understanding how altered levels (and presumably activity) of initiation factors can contribute to tumor initiation and/or maintenance is of major interest for the development of novel therapeutic strategies. In this review we provide an overview of translation initiation mechanisms and focus on recent findings describing the role of individual initiation factors and their aberrant activity in cancer.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; protein synthesis; translation; translation initiation; translational control

Mesh:

Substances:

Year:  2016        PMID: 27426745     DOI: 10.1016/j.tcb.2016.06.005

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  52 in total

1.  Estrogen receptor α promotes protein synthesis by fine-tuning the expression of the eukaryotic translation initiation factor 3 subunit f (eIF3f).

Authors:  Rafael Cuesta; Adi Y Berman; Anya Alayev; Marina K Holz
Journal:  J Biol Chem       Date:  2018-12-20       Impact factor: 5.157

2.  Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Authors:  Cole Peters; Max Paget; Kizito-Tshitoko Tshilenge; Dipongkor Saha; Slawomir Antoszczyk; Anouk Baars; Thomas Frost; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

3.  Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.

Authors:  Adeola O Adebayo Michael; Sungjin Ko; Junyan Tao; Akshata Moghe; Hong Yang; Meng Xu; Jacquelyn O Russell; Tirthadipa Pradhan-Sundd; Silvia Liu; Sucha Singh; Minakshi Poddar; Jayvir S Monga; Pin Liu; Michael Oertel; Sarangarajan Ranganathan; Aatur Singhi; Sandra Rebouissou; Jessica Zucman-Rossi; Silvia Ribback; Diego Calvisi; Natalia Qvartskhava; Boris Görg; Dieter Häussinger; Xin Chen; Satdarshan P Monga
Journal:  Cell Metab       Date:  2019-01-31       Impact factor: 27.287

4.  Crystal Structure of the C-terminal Domain of Human eIF2D and Its Implications on Eukaryotic Translation Initiation.

Authors:  Anand T Vaidya; Ivan B Lomakin; Newlyn N Joseph; Sergey E Dmitriev; Thomas A Steitz
Journal:  J Mol Biol       Date:  2017-07-21       Impact factor: 5.469

5.  Decapping enzymes STOP "cancer" ribosomes in their tracks.

Authors:  Jeffrey S Mugridge; John D Gross
Journal:  EMBO J       Date:  2018-11-19       Impact factor: 11.598

6.  Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity.

Authors:  Tara L Peters; Joseph Tillotson; Alison M Yeomans; Sarah Wilmore; Elizabeth Lemm; Carlos Jiménez-Romero; Luis A Amador; Lingxiao Li; Amit D Amin; Praechompoo Pongtornpipat; Christopher J Zerio; Andrew J Ambrose; Gillian Paine-Murrieta; Patricia Greninger; Francisco Vega; Cyril H Benes; Graham Packham; Abimael D Rodríguez; Eli Chapman; Jonathan H Schatz
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

7.  Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Authors:  Long-Sheng Chang; Janet L Oblinger; Sarah S Burns; Jie Huang; Larry W Anderson; Melinda G Hollingshead; Rulong Shen; Li Pan; Garima Agarwal; Yulin Ren; Ryan D Roberts; Barry R O'Keefe; A Douglas Kinghorn; Jerry M Collins
Journal:  Mol Cancer Ther       Date:  2019-12-17       Impact factor: 6.261

Review 8.  Developing anti-neoplastic biotherapeutics against eIF4F.

Authors:  Jutta Steinberger; Jennifer Chu; Rayelle Itoua Maïga; Katia Sleiman; Jerry Pelletier
Journal:  Cell Mol Life Sci       Date:  2016-12-21       Impact factor: 9.261

Review 9.  Therapeutic Opportunities in Eukaryotic Translation.

Authors:  Jennifer Chu; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 10.  Ribosomal biogenesis as an emerging target of neurodevelopmental pathologies.

Authors:  Michal Hetman; Lukasz P Slomnicki
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.